CRISPR-mediated genome editing and human diseases

Liquan Cai, Alfred L. Fisher, Haochu Huang, Zijian Xie

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a powerful technology for genome editing and is now widely used in basic biomedical research to explore gene function. More recently, this technology has been increasingly applied to the study or treatment of human diseases, including Barth syndrome effects on the heart, Duchenne muscular dystrophy, hemophilia, β-Thalassemia, and cystic fibrosis. CRISPR/Cas9 (CRISPR-associated protein 9) genome editing has been used to correct disease-causing DNA mutations ranging from a single base pair to large deletions in model systems ranging from cells in vitro to animals in vivo. In addition to genetic diseases, CRISPR/Cas9 gene editing has also been applied in immunology-focused applications such as the targeting of C-C chemokine receptor type 5, the programmed death 1 gene, or the creation of chimeric antigen receptors in T cells for purposes such as the treatment of the acquired immune deficiency syndrome (AIDS) or promoting anti-tumor immunotherapy. Furthermore, this technology has been applied to the genetic manipulation of domesticated animals with the goal of producing biologic medical materials, including molecules, cells or organs, on a large scale. Finally, CRISPR/Cas9 has been teamed with induced pluripotent stem (iPS) cells to perform multiple tissue engineering tasks including the creation of disease models or the preparation of donor-specific tissues for transplantation. This review will explore the ways in which the use of CRISPR/Cas9 is opening new doors to the treatment of human diseases.

Original languageEnglish (US)
Pages (from-to)244-251
Number of pages8
JournalGenes and Diseases
Volume3
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Genes
Technology
Barth Syndrome
Animals
Immunology
Tissue Transplantation
Induced Pluripotent Stem Cells
CC Chemokines
Inborn Genetic Diseases
Antigen Receptors
Thalassemia
T-cells
Duchenne Muscular Dystrophy
Chemokine Receptors
Domestic Animals
Hemophilia A
Tissue Engineering
T-Cell Antigen Receptor
Allergy and Immunology

Keywords

  • CRISPR
  • DNA double-stranded break
  • Genome editing
  • Human diseases
  • iPS cells

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology

Cite this

CRISPR-mediated genome editing and human diseases. / Cai, Liquan; Fisher, Alfred L.; Huang, Haochu; Xie, Zijian.

In: Genes and Diseases, Vol. 3, No. 4, 01.12.2016, p. 244-251.

Research output: Contribution to journalReview article

Cai, Liquan ; Fisher, Alfred L. ; Huang, Haochu ; Xie, Zijian. / CRISPR-mediated genome editing and human diseases. In: Genes and Diseases. 2016 ; Vol. 3, No. 4. pp. 244-251.
@article{844434c5b26e42a9819a8847e4bfdeab,
title = "CRISPR-mediated genome editing and human diseases",
abstract = "CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a powerful technology for genome editing and is now widely used in basic biomedical research to explore gene function. More recently, this technology has been increasingly applied to the study or treatment of human diseases, including Barth syndrome effects on the heart, Duchenne muscular dystrophy, hemophilia, β-Thalassemia, and cystic fibrosis. CRISPR/Cas9 (CRISPR-associated protein 9) genome editing has been used to correct disease-causing DNA mutations ranging from a single base pair to large deletions in model systems ranging from cells in vitro to animals in vivo. In addition to genetic diseases, CRISPR/Cas9 gene editing has also been applied in immunology-focused applications such as the targeting of C-C chemokine receptor type 5, the programmed death 1 gene, or the creation of chimeric antigen receptors in T cells for purposes such as the treatment of the acquired immune deficiency syndrome (AIDS) or promoting anti-tumor immunotherapy. Furthermore, this technology has been applied to the genetic manipulation of domesticated animals with the goal of producing biologic medical materials, including molecules, cells or organs, on a large scale. Finally, CRISPR/Cas9 has been teamed with induced pluripotent stem (iPS) cells to perform multiple tissue engineering tasks including the creation of disease models or the preparation of donor-specific tissues for transplantation. This review will explore the ways in which the use of CRISPR/Cas9 is opening new doors to the treatment of human diseases.",
keywords = "CRISPR, DNA double-stranded break, Genome editing, Human diseases, iPS cells",
author = "Liquan Cai and Fisher, {Alfred L.} and Haochu Huang and Zijian Xie",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.gendis.2016.07.003",
language = "English (US)",
volume = "3",
pages = "244--251",
journal = "Genes and Diseases",
issn = "2352-3042",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - CRISPR-mediated genome editing and human diseases

AU - Cai, Liquan

AU - Fisher, Alfred L.

AU - Huang, Haochu

AU - Xie, Zijian

PY - 2016/12/1

Y1 - 2016/12/1

N2 - CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a powerful technology for genome editing and is now widely used in basic biomedical research to explore gene function. More recently, this technology has been increasingly applied to the study or treatment of human diseases, including Barth syndrome effects on the heart, Duchenne muscular dystrophy, hemophilia, β-Thalassemia, and cystic fibrosis. CRISPR/Cas9 (CRISPR-associated protein 9) genome editing has been used to correct disease-causing DNA mutations ranging from a single base pair to large deletions in model systems ranging from cells in vitro to animals in vivo. In addition to genetic diseases, CRISPR/Cas9 gene editing has also been applied in immunology-focused applications such as the targeting of C-C chemokine receptor type 5, the programmed death 1 gene, or the creation of chimeric antigen receptors in T cells for purposes such as the treatment of the acquired immune deficiency syndrome (AIDS) or promoting anti-tumor immunotherapy. Furthermore, this technology has been applied to the genetic manipulation of domesticated animals with the goal of producing biologic medical materials, including molecules, cells or organs, on a large scale. Finally, CRISPR/Cas9 has been teamed with induced pluripotent stem (iPS) cells to perform multiple tissue engineering tasks including the creation of disease models or the preparation of donor-specific tissues for transplantation. This review will explore the ways in which the use of CRISPR/Cas9 is opening new doors to the treatment of human diseases.

AB - CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a powerful technology for genome editing and is now widely used in basic biomedical research to explore gene function. More recently, this technology has been increasingly applied to the study or treatment of human diseases, including Barth syndrome effects on the heart, Duchenne muscular dystrophy, hemophilia, β-Thalassemia, and cystic fibrosis. CRISPR/Cas9 (CRISPR-associated protein 9) genome editing has been used to correct disease-causing DNA mutations ranging from a single base pair to large deletions in model systems ranging from cells in vitro to animals in vivo. In addition to genetic diseases, CRISPR/Cas9 gene editing has also been applied in immunology-focused applications such as the targeting of C-C chemokine receptor type 5, the programmed death 1 gene, or the creation of chimeric antigen receptors in T cells for purposes such as the treatment of the acquired immune deficiency syndrome (AIDS) or promoting anti-tumor immunotherapy. Furthermore, this technology has been applied to the genetic manipulation of domesticated animals with the goal of producing biologic medical materials, including molecules, cells or organs, on a large scale. Finally, CRISPR/Cas9 has been teamed with induced pluripotent stem (iPS) cells to perform multiple tissue engineering tasks including the creation of disease models or the preparation of donor-specific tissues for transplantation. This review will explore the ways in which the use of CRISPR/Cas9 is opening new doors to the treatment of human diseases.

KW - CRISPR

KW - DNA double-stranded break

KW - Genome editing

KW - Human diseases

KW - iPS cells

UR - http://www.scopus.com/inward/record.url?scp=85018083663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018083663&partnerID=8YFLogxK

U2 - 10.1016/j.gendis.2016.07.003

DO - 10.1016/j.gendis.2016.07.003

M3 - Review article

C2 - 30258895

AN - SCOPUS:85018083663

VL - 3

SP - 244

EP - 251

JO - Genes and Diseases

JF - Genes and Diseases

SN - 2352-3042

IS - 4

ER -